In Vitro Activity of the New Triazole Voriconazole (UK-109,496) against Opportunistic Filamentous and Dimorphic Fungi and Common and Emerging Yeast Pathogens

Abstract

ABSTRACT The in vitro antifungal activity of a new triazole derivative, voriconazole, was compared with those of itraconazole and amphotericin B against 67 isolates of Aspergillus flavus , Aspergillus fumigatus , Bipolaris spp., Fusarium oxysporum , Fusarium solani , Pseudallescheria boydii , Rhizopus arrhizus , Blastomyces dermatitidis , Histoplasma capsulatum , and Sporothrix schenckii . The in vitro activities of voriconazole were also compared with those of amphotericin B, fluconazole, and itraconazole against 189 isolates of emerging and common yeast pathogens of Blastoschizomyces capitatus , Candida (13 species), Cryptococcus neoformans , Hansenula anomala , Rhodotorula rubra , Saccharomyces cerevisiae , Sporobolomyces salmonicolor , and Trichosporon beigelii . MICs were determined according to a procedure under evaluation by the National Committee for Clinical Laboratory Standards (NCCLS) for broth microdilution testing of filamentous fungi and by the NCCLS M27-A broth microdilution method for yeasts. The in vitro activities of voriconazole were similar to or better than those of itraconazole and amphotericin B against Aspergillus spp., Fusarium spp., and P. boydii as well as against B. dermatitidis and H. capsulatum . The activities of voriconazole were also comparable to or better than those of amphotericin B, fluconazole, and itraconazole against most species of yeasts tested. Exceptions were certain isolates of R. rubra and S. salmonicolor . These results suggest that voriconazole has a wide spectrum of activity in vitro; its effectiveness in the treatment of human mycoses is under evaluation in clinical trials.